Sara Tolaney: Helpful discussion by Cristina Saura on how to think about adjuvant therapies in patients with gBRCAm

Sara Tolaney shared a post on X:

“Very helpful discussion by Cristina Saura on how to think about adjuvant therapies in patients with gBRCAm.

Could we consider sequential adjuvant abemaciclib after olaparib in high-risk pts with ER and BC and gBRCAm?”

Source: Sara Tolaney/X

Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches.